Susquehanna International Group’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History

Susquehanna International Group’s Portfolio BCTXW Stock Details BCTXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-67,111	Closed	-$3.54K	–	13164
2025 Q4	$3.54K	Buy	+67,111	New	+$3.35K	﹤0.01%	12112
2025 Q2	–	Sell	-16,246	Closed	-$1.44K	–	12651
2025 Q1	$1.44K	Buy	+16,246	New	+$2.25K	﹤0.01%	12313
2022 Q2	–	Sell	-16,092	Closed	-$84K	–	12877
2022 Q1	$84K	Buy	+16,092	New	+$64.1K	﹤0.01%	12020

Susquehanna International Group's BCTXW Position: Q1 2026 in Review

Susquehanna International Group sold out of BriaCell Therapeutics Corp Warrant (BCTXW) in Q1 2026, closing a stake of 67,111 shares — an estimated $3.54K sold.

Susquehanna International Group first reported a position in BCTXW in Q1 2022 and held it in 3 quarters. The position peaked at $84K in Q1 2022. 0 funds tracked by Wall St. Rank hold BCTXW as of Q1 2026.

Susquehanna International Group reported no remaining BriaCell Therapeutics Corp Warrant position as of Q1 2026 after selling out during the quarter.
Susquehanna International Group sold 67,111 BriaCell Therapeutics Corp Warrant shares in Q1 2026, an estimated $3.54K.
Susquehanna International Group first reported a position in BriaCell Therapeutics Corp Warrant in Q1 2022 and held it in 3 quarters.
Susquehanna International Group's BriaCell Therapeutics Corp Warrant position peaked at $84K in Q1 2022.
0 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.